Other Deal Trends 2026: Activity Surges 3900% in 6 Months

39 deals classified outside traditional therapeutic area boundaries closed between January 23 and July 23, 2026 — a +3900% increase over the prior six-month window, which recorded exactly zero. This isn't a rounding error or a taxonomic quirk. It's a structural shift in how Big Pharma is deploying capital: away from narrow indication-specific licensing and toward platform acquisitions, enabling technology plays, and cross-cutting capability deals that don't fit cleanly into oncology, immunology, or neuroscience buckets. The other licensing 2026 wave reflects pharma's growing appetite for horizontal bets — protein engineering platforms, AI-native drug design engines, and geographic market access deals — that create optionality across multiple therapeutic areas simultaneously.

The Data — Other Deal Activity, Period over Period

Zero to 39 in six months. The absolute number matters less than what it signals: dealmakers are increasingly structuring transactions that span modalities, geographies, or technology layers in ways that resist conventional TA classification. When you use the Deal Benchmarks tool to compare these transactions, the heterogeneity is striking — total deal values range from mid-nine-figure licensing arrangements to $11.3B outright acquisitions. This is a category defined by strategic ambition, not therapeutic focus.

What's Driving the Trend

Three forces converge to explain the other deal trends 2026 surge. First, platform fatigue has given way to platform urgency. For two years, pharma leadership teams debated the merits of acquiring AI-driven drug design capabilities versus building internally. That debate is over. Generate: Biomedicines' deal with Novartis on June 28, 2026 signals that even the most R&D-capable pharma companies have concluded that generative biology platforms are faster to buy than to build. The deals that don't fit a single TA are precisely the ones that give pharma optionality across five or ten programs simultaneously — and that optionality premium is now priced into deal structures.

Second, geographic access deals are accelerating. YaoPharma's $150M upfront / $2.05B TDV deal with Pfizer is emblematic. These aren't traditional out-licensing arrangements; they're market-entry partnerships where a Chinese or regional biotech provides manufacturing, regulatory, and commercial infrastructure in exchange for economics that look more like co-development than licensing. As pharma companies face pricing pressure in the U.S. and Europe, the strategic value of emerging-market access vehicles has climbed. These deals inherently resist TA classification because they often cover portfolios, not single assets.

Third, the enabling technology layer — reagents, biologics tools, protein engineering — has become a strategic acquisition target rather than a vendor relationship. Bio-Techne's $11.3B transaction with Merck KGaA is the clearest proof point. This is not a pipeline deal. It's a capability deal: acquiring the infrastructure that makes drug development faster and cheaper across every therapeutic area. When a single tools company commands an $11.3B price tag, it tells you the market has repriced the value of horizontal platforms relative to vertical pipeline assets.

Notable Deals

Bio-Techne / Merck KGaA ($11.3B): This is the deal that defines 2026 H1. Merck KGaA paid a significant premium to acquire a biologics tools and reagents platform — not a drug, not a pipeline, but the picks-and-shovels infrastructure underlying biologics development globally. At $11.3B, this is one of the largest enabling-technology acquisitions in biopharma history. The strategic logic is sound: Bio-Techne's protein sciences portfolio gives Merck KGaA a defensible position in the biologics supply chain regardless of which drugs or modalities ultimately win. It's a hedge on the entire industry. For BD teams benchmarking platform acquisitions, run comparable multiples through the Deal Calculator — revenue multiples here likely exceed 10x, reflecting scarcity value.

Generate: Biomedicines / Novartis: Financial terms undisclosed, which itself is telling — Novartis rarely keeps deal economics quiet unless the structure is non-traditional (equity, options on future programs, milestone-heavy). Generate's generative biology platform produces novel protein therapeutics computationally. This deal validates the thesis that AI-native drug design is now a board-level strategic priority, not an innovation sidecar. Expect disclosure of terms in Novartis's Q3 earnings or an upcoming SEC filing.

YaoPharma / Pfizer ($150M upfront / $2.05B TDV): A geographic access play. Pfizer is paying meaningful upfront capital to secure China market infrastructure through YaoPharma. The upfront-to-TDV ratio (~7.3%) is lean, suggesting heavy milestone loading and significant commercial-stage economics. This structure protects Pfizer's downside while giving YaoPharma skin-in-the-game economics that look more like a JV than a license.

What This Means for BD Teams Right Now

If you're selling a platform or enabling technology asset, this is the strongest seller's market in memory for horizontal plays. The Bio-Techne precedent resets valuation expectations for any company with defensible tools, reagents, or platform technology that spans multiple TAs. Don't anchor to comps from 2024 — the market has moved. Use the Deal Benchmarks database to pull H1 2026 comparables and adjust your ask accordingly.

If you're buying, move fast on generative biology and AI-native design platforms. The Novartis/Generate deal removed a significant asset from the market. The remaining independent platforms — and there are fewer than a dozen with clinical-stage validation — will attract multiple bidders by Q4 2026. Waiting six months will cost you 20–40% in premium, based on the acceleration curve we're tracking in other deal trends 2026.

Deal structures are shifting in this category. Pure royalty-based licensing is giving way to hybrid structures: upfront equity stakes combined with option-to-acquire provisions, co-development agreements with milestone step-ups, and portfolio-wide frameworks rather than single-asset licenses. BD teams should build flexibility into term sheets. The deals getting done fastest are the ones where both sides accept structural complexity in exchange for aligned incentives.

For geographic access deals specifically, upfront-to-TDV ratios in the 5–10% range appear to be the new normal. Sellers pushing for 15%+ upfronts on China or emerging-market deals are getting pushback. The YaoPharma/Pfizer structure — lean upfront, milestone-heavy, with commercial-stage economics driving TDV — is the template other BD teams should study.

Benchmark your deal against current market rates. Whether you're structuring a platform acquisition, an AI licensing deal, or a geographic partnership, the Ambrosia calculator lets you stress-test your economics against verified 2026 comparables — including the transactions profiled here.